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Abstract 
Eye Plaque brachytherapy pre-treatment quality assurance (QA) conducted clinically involves an activity 
verification of individual seeds via well chamber and does not include a physical measurement of dose-
rate of the final assembly. A novel spectroscopic, dose-rate detection system, was evaluated for pre-
treatment QA of eye plaque brachytherapy. The system includes a water phantom with sterility 
management. The system was calibrated using a known-activity I-125 seed, measured at 1 cm in water 
along the radial axis, compared to TG-43 U1 calculations and verified over a number of distances. A depth 
dose curve was acquired for a clinical, mixed activity eye plaque and two 'error' plaques. The probe was 
stepped from a water equivalent source to a detector distance (SDD) of 2.5 to 12 mm along the plaque 
central axis. The latter measurements aimed to characterise the sensitivity of the system. The calculated 
and measured single-seed dose-rates agreed to within 0.5 cGy/h from a SDD of 3 mm and above. The 
clinical plaque showed agreement between measured and treatment planning system (TPS) calculated 
dose-rates within 2%. Sensitivity testing resulted in a maximum deviation from TPS data of 18%, therefore 
was able to detect the presence of packing errors. The dose-rate detection system was successfully 
evaluated for verification of I-125 based eye plaques without compromising sterility, allowing for quick 
pre-treatment, dose-rate verification of patient-ready plaques. Its agreement with TPS data for the 
unmodified plaque and its deviation when introducing errors confirms the approach suggested is a viable 
QA tool. 
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ABSTRACT 
Eye Plaque brachytherapy pre-treatment quality assurance (QA) conducted clinically involves an activity 
verification of individual seeds via well chamber and does not include a physical measurement of dose-rate of the 
final assembly. A novel spectroscopic, dose-rate detection system, is evaluated for pre-treatment QA of eye plaque 
brachytherapy. The system includes a water phantom with sterility management. 
The system was calibrated using a known-activity I-125 seed, measured at 1 cm in water along the radial axis, 
compared to TG-43 U1 calculations and verified over a number of distances. A depth dose curve was acquired 
for a clinical, mixed activity eye plaque and two ‘error’ plaques. The probe was stepped from a water equivalent 
source to a detector distance (SDD) of 2.5 to 12 mm along the plaque central axis. The latter measurements aimed 
to characterise the sensitivity of the system. 
The calculated and measured single-seed dose-rates agreed to within 0.5 cGy/hr from a SDD of 3 mm and above. 
The clinical plaque showed agreement between measured and treatment planning system (TPS) calculated dose-
rates within 2%. Sensitivity testing resulted in a maximum deviation from TPS data of 18%, therefore was able 
to detect the presence of packing errors. 
The dose-rate detection system was successfully evaluated for verification of I-125 based eye plaques without 
compromising sterility, allowing for quick pre-treatment, dose-rate verification of patient-ready plaques. Its 
agreement with TPS data for the unmodified plaque and its deviation when introducing errors confirms the 
approach suggested is a viable QA tool. 
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Eye plaque brachytherapy can be used for the treatment of small and medium-sized ocular tumours, with survival 
rates consistent with enucleation [1]. Treatment is commonly conducted using Iodine-125 sources, which have a 
primary photon emission of approximately 27 keV [2]. Dose delivery is achieved by placing the eye plaque 
adjacent to the treatment volume and the total duration of treatment is determined by measuring the average 
activity of the sources. Clinical dose-rates range between approximately 0.60-1.05 Gy/hr [3]. 
AAPM task group 129 (TG129) reviewed the dosimetry of eye plaques for intraocular tumours, finding that for 
an average treatment prescription of 85 Gy at 5 mm depth in a homogenous medium, just 75 Gy was actually 
delivered during treatment [4]. The relationship between the cumulative activity of the seeds and dose-rate is 
formalised in the update to AAPM task group 43 (TG-43), however clinical eye plaque brachytherapy conditions 
depart from ideal measurement conditions, suggesting a need to advance plaque dosimetry [5]. Any potential QA 
protocol is problematic as each component of the plaque must remain sterile prior to patient implantation. 
Currently, no dose-rate measurements of the loaded plaque are taken to verify the dose-rate of the plaque and 
conformance to the TPS plan [6].  
Some studies have utilised gel dosimetry as a means to measure the dose of a clinical eye plaque [7]. Advantages 
of gel dosimetry include a high spatial resolution and can achieve a close proximity to the plaque. However gel 
does not have an instantaneous read-out and the signal acquired is dependent on the time spent in contact with the 
radiation source, often taking hours to acquire a usable signal. Maintaining the sterility of the plaque during the 
pre-insertion QA would also prove problematic.  
Dosimeters such as film and TLDs have also been used in the context of TPS verification of eye plaque 
brachytherapy planning [8]. Similarly to gel, film and TLDs require time to process the signal due to dose and can 
only obtain an integral measurement. Uncertainties of approximately 5% are expected when using these 
dosimeters [8]. A review of literature found the existence of QA devices for eye plaque QA is currently limited 
and many centres offering the treatment have developed bespoke systems based primarily on using the above 
dosimeters [9], outlining a clinical need for a new QA system that could increase efficiency and help standardise 
practise. 
A previously published silicon dosimeter designed for eye plaque QA was shown to be accurate at a distance of 
1 cm from the plaque surface, but was ultimately found to be unsuitable due to substantial angular dependence 
and included no provisions to maintain a sterile plaque environment [10, 11]. Presented in this paper is the new 
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iteration of that system, which aimed to accurately determine the dose-rate of a clinical plaque and to develop a 
measurement apparatus that addresses the unique challenges involved in eye plaque brachytherapy quality 
assurance. 
2. METHOD  
2.A Equipment 
2.A.1 ROPES Eye Plaque 
The Radiation and Oncology Physics and Engineering Services, Australia (ROPES) 15 mm eye plaque includes 
an acrylic insert, holding up to 10 seeds, and a stainless steel applicator. The insert serves to position the seeds 1 
mm from the sclera of the eye in two concentric rings about the plaque central axis, as seen in figure 1. The 
stainless steel applicator is a spherical shell that encapsulates the mould, shielding normal tissue from treatment 
photons.  
2.A.2 Edgeless Silicon diode for dosimetry 
The eye plaque brachytherapy probe was constructed using an ‘edgeless’ diode, shown in figure 2a. The sensitive 
volume has dimensions of 0.5 mm x 0.5 mm x 0.1 mm volume and is operated in reverse bias at -4.5 V. As per 
its edgeless design, the N+ electrode encapsulates most of the silicon substrate volume of the diode, minimising 
its angular dependence to within ± 2% over 360° [12]. The high resistivity of the substrate (10kOhm-cm) allows 
to operate the detector at low bias with no deterioration of its charge collection efficiency. 
The diode is mounted to the tip of a PCB, containing a field effect transistor for initial signal amplification and a 
preamplifier circuit for transmission to the microprocessor unit. This circuitry is housed within a 3D printed plastic 
cover, placing the sensitive volume 1.5 mm from the external surface of the probe tip. The packaged probe can be 
seen in figure 2b.  
 
2.A.3 Microprocessor unit 
As shown in figure 3, the Microprocessor unit was used to interpret and process the amplified signal from the 
probe. The unit contains a shaping amplifier, on-board microprocessor as well as adjustable inputs for accurate 
calibration. 
A pulse-by-pulse detection mode was employed, enabling spectroscopic analysis of the signal and the setting of 
a manual energy threshold. Previous studies concluded the Iodine-125 brachytherapy seed spectrum can be 
averaged such that each pulse can be counted as a 27 keV event [13]. This approximation, which facilitated fast 
signal processing, is valid due to the relative symmetry of the spectrum and average energy occurring within the 
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most intense photopeak. The microprocessor approximates all counts above the energy threshold to this same 
energy, enabling the system to have fast processing times and a linear dose response. The gain of the unit was 
adjusted during calibration to relate this signal to dose. The energy threshold is set such that low energy scatter, 
characteristic x-rays from metallic probe components and electronic noise can be filtered out, resulting in a more 
accurate and reliable reading. 
 
2.A.4 Phantom/motorised stage 
A cylindrical water phantom with height 140 mm and a diameter of 175 mm was designed and fabricated from 
3D printed Visijet Crystal. For short-ranged I-125 photons, the phantom is effectively an infinite water bath and 
hence satisfied TG-43 U1 assumptions. The tank contains a waterproof void where the plaque is held during 
measurements, extending out from the base of the tank into the centre of the water bath. The plastic membrane 
separating the plaque chamber from the water is just 0.5 mm thick, a limitation of the 3D printer and materials 
adopted, and is a hemisphere in shape, to conform to the ROPES 15 mm plaque curvature.  
To preserve the sterility of the eye plaque for surgical insertion, a plug was designed to house and position the 
plaque in the waterproof cavity under the water bath, as seen in figure 5. The plaque is placed in the curved 
receptacle of the plug and is secured with a 0.5 mm thick retaining cap, resulting in a total thickness of 1 mm of 
plastic between the detector tip and the plaque surface. A minimum distance of 2.5 mm between the sensitive 
volume of the probe and surface of the plaque exists during sterile measurement. The plug is screwed into the 
cavity and locked into the measurement position. Due to their modular and distinct design, these 3D-printed 
components are able to be sterilised.  
Prior to dosimetric measurements, accurate dose-rate calibration is necessary. This process requires the 
measurement of a single seed in the water phantom. A 3D printed calibration cap was designed to ensure reliable 
positioning of the seed shown in figure 6. This cap was designed to sit in the water bath of the phantom and 
resulting in a minimum distance of 1.5 mm between the sensitive volume and seed surface.  
A linear stage was used to position the probe vertically along the central axis of the plaque and facilitated accurate 
and reproducible positioning of the probe relative to the surface of the eye plaque. The minimum step size 




Calibration of the eye plaque verification system involves adjusting the gain of the signal processing system such 
that the dose-rate displayed matched that of a single seed source.  
The activity of the calibration seed was measured with a traceable well chamber and used to determine the dose-
rate at a distance of 10 mm along the source central axis. This seed was then inserted into the calibration cap and 
secured within the water tank. Using the linear stage, the probe was lowered into the water bath until the external 
tip of the probe made contact with the seed, establishing its reference home position. Due to the 1.5 mm separation 
between the probe tip and the actual detector, the probe was raised 8.5 mm, placing the sensitive volume 10 mm 
from the cap. The gain of the read-out system was adjusted to match the dose-rate (cGy/hr) determined using the 
previously measured seed activity with the well chamber. 
The response of the detector was characterised post-calibration by measuring the dose-rate of the seed as a function 
of distance. Measurements were undertaken between 0 mm to 12 mm from the seed surface with 0.5 mm 
increments. The calibrated dose-rate profile was compared to TG43 U1 calculations, as shown in figure 7. Good 
agreement was observed for all measurements at a distance greater than 2 mm, with slight probe misalignment 
suspected to be the cause for deviations at shorter distances. Alternatively, attenuation of the 3D-printed, plastic 
cover of the probe maybe have altered the spectrum relative to water, at a close proximity, reducing the dose-rate.  
In addition, there are relatively large uncertainties for distances of less than 2 mm from the seed surface in TG-43 
U1 tabulated data, of approximately ±4%. 
 
2.B.2 Full plaque Measurement 
The eye plaque verification system was evaluated using a 10-seed clinical plan. A loaded ROPES plaque was 
positioned in the waterproof cavity of the water phantom and placed in the measurement position. The probe was 
moved to its reference position and the dose-rate measured at 0.5 mm increments up to 12 mm from the plaque 
surface. Due to the additional plastic layers of the phantom, the minimum distance between the plaque surface 
and the detector was 2.5 mm. 
Sensitivity testing of the quality assurance system was conducted by introducing a variety of packing errors into 
the 10-seed plaque. The plaque was packed using a mixed distribution of 3.841 mCi and 1.556 mCi seeds, as per 
the clinical plan, however a single central high activity seed was replaced with a seed of the lower activity. A 
second scenario was tested with seeds of a similar activity, 4.022 mCi and 1.652 mCi, where a low activity seed 
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positioned in the outer ring was replaced with a high activity seed. A diagram of the seed positioning can be seen 
in Figure 1. 
To evaluate the uncertainty of experimental measurements, a minimum of three independent readings, were 
acquired per read-out position and the standard deviation of the mean determined.  
3. Results  
3.A Clinical plan verification 
Figure 8 shows a comparison between the measured dose rates using the eye plaque verification system and the 
calculated values from the TPS for the correctly loaded 10-seed plaque. Measured dose-rates agree with all TPS 
values between 3 mm and 13 mm, with a maximum deviation of approximately 2% when the detector tip is closest 
to the plaque. At this position, I-125 photons are incident on the sensitive volume at a solid angle of approximately 
𝜋𝜋 steradians is subtended by the source on plaque surface, as the detector is located inside the concavity of the 
plaque. Therefore the 2% discrepancy between planned and measured dose-rates are consistent with the  
uncertainties of tabulated dose-rate data in close proximity to brachytherapy seed surfaces and the angular 
dependence of the edgeless diode design [12]. 
 
3.B Central ring packing error verification 
Figure 9 shows a comparison of measured and planned dose rates for the 10-seed plaque, with a high activity, 
central seed replaced by a seed with a lower activity. Measured dose rates were significantly lower than planned 
values at distances 2.5 – 6 mm, with a maximum deviation of 18% at 2.5 mm. The deviation between measured 
and planned values decreases as a function of distance due to the short range of I-125 photons, resulting in very 
small discrepancy in photon intensity between the planned and measured case at large distances.  
 
3.C Outer ring packing error verification 
Figure 11 shows the comparison of measured and planned dose rates for the 10 seed plaque, however with a lower 
activity seed replaced with a high activity seed in the outer ring of the plaque. Measured dose rates exceeded 
planned values by approximately 6 – 9% at all measurement locations. The sensitivity of the QA system is such 
that it can detect a misplaced seed in outer ring of the plaque, which relative to the useful range of I-125 photons, 
is significantly further from the detector than a centrally located seed.  
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For both error verification cases, the observed discrepancies would warrant the clinical physicist to unpack the 
plaque and use the well-chamber to remeasure each individual seed to verify their activity, and to ensure the 
correct seed placement in the plaque before treatment could commence. 
4. Discussion 
The clinical eye plaque dose-rate dosimetry system has acquired depth dose curves in close agreement to both 
TG-43 U1 for a single seed case and the TPS for a clinical planned plaque within 1% and 2%, respectively. This 
includes measurement points in close proximity (<5 mm) to the radiation source, in a region where preceding 
publications have reported results with limited dosimetric agreement to theory. Jarema [10] reported deviations 
between TG-43 U1 calculations and measured dose-rates to be just 1% at 10 mm from the surface of the eye 
plaque, however deviations of up to 15% were discovered at distances of less than 5 mm and were attributed to 
significant angular dependence of that dosimeter [11]. 
As demonstrated by the small discrepancy between calculated depth dose and measured values of the clinical eye 
plaque at shallow depths (figure 9), there still exists some angular dependence in the new probe. However, there 
are also significant uncertainties involved in the measurement of low energy sources such as I-125, due to the 
extremely sharp dose gradients they exhibit. Therefore, an accurate determination of the diodes sensitive volume 
position and distance is required for eye plaque QA using this spectroscopic dosimetry system, followed by the 
precise calibration as used in this work. 
The shallow depth region has been shown to be clinically significant as the largest deviations measured in the 
‘error’ plaques were present at distances below 5 mm. As the intent of the dosimetry system was to perform quality 
assurance on clinical plaques, accuracy and reliability of measurement of the dose in regions most sensitive to 
variation is crucial.  
The QA system calibration method depends on the linearity of microprocessor, such that a one point calibration 
remains valid over the range of measurements. Uncertainty in the dose linearity of the system may be attributed 
to a suboptimal placement of the energy threshold, particularly in the presence of electronic noise.  In addition, 
the discrete timing characteristics of the pulse-by-pulse detection may also introduce uncertainty in the dose rate. 
The system does not include an on-board background signal compensator. Under very high dose-rate conditions 
the micro-processor does have a risk of dead time and pile up, as one pulse is being processed, another may have 
been generated, but not counted. The result of this would be an underestimation of the dose-rate, most likely 
present at close proximity to the photon source.  
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Another source of uncertainty is the 3D-printed phantom composition. Visijet plastic is proprietary, therefore the 
exact composition of the material is unclear and the impact of non-water equivalent material is difficult to 
quantify. The close conformance of experimental result to theory for both a single seed and a clinical plaque, 
suggests that for a I-125 spectrum, the material is approximately water equivalent, albeit with a slightly higher 
density as could be expected by a polyethylene based plastic. The calibration method may also account for any 
energy dependence of the material, as acquisitions are normalised to 10 mm and can be compensated by the gain 
settings.  
It is recommended that clinical implementation of the fast read-out, spectroscopic dosimeter includes the 
measured dose-rate at both shallow and larger depths to be compared with the corresponding TPS values, ensuring 
an accurate and reliable depth dose verification.  
 
5. Conclusion 
The eye plaque brachytherapy QA system developed has been shown to be a viable clinical tool for dose-rate 
verification of eye plaques prior to patient insertion. The system displayed the ability to detect even single-seed 
plaque packing errors, in both the central and outer sections of the plaque while maintaining plaque sterility. No 
other QA solutions currently available measure the instantaneous dose rate of a clinical plaque prior to patient 
insertion, in addition, other dosimeters require large signal acquisition, calibration and analysis time, while the 
system presented offers fast, stream-lined measurement output. Despite small uncertainties in detector localisation 
and the presence of an air gap in the detector tip, the calibrated system achieves a 2% agreement with TPS 
calculations at 2.5 mm from the plaque surface and easily discerns introduced dose-rate deviations.  
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Fig. 10 Dose rate comparison of a plaque packed according to the TPS and a plaque where a 3.841 mCi inner 
























Fig. 11 Dose rate comparison of a plaque packed according to the TPS and a plaque where a 1.652  mCi outer 
ring seed  was replaced by a seed with an activity of 4.022 mCi 
